Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TIRZEPATIDE Cause Prostatic specific antigen increased? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Prostatic specific antigen increased have been filed in association with TIRZEPATIDE (Zepbound). This represents 0.0% of all adverse event reports for TIRZEPATIDE.

7
Reports of Prostatic specific antigen increased with TIRZEPATIDE
0.0%
of all TIRZEPATIDE reports
0
Deaths
0
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From TIRZEPATIDE?

Of the 7 reports.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TIRZEPATIDE. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does TIRZEPATIDE Cause?

Incorrect dose administered (23,301) Injection site pain (10,989) Nausea (10,018) Off label use (7,007) Extra dose administered (6,774) Diarrhoea (5,463) Vomiting (4,635) Injection site haemorrhage (4,389) Accidental underdose (3,897) Injection site erythema (3,844)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)

Which TIRZEPATIDE Alternatives Have Lower Prostatic specific antigen increased Risk?

TIRZEPATIDE vs TISAGENLECLEUCEL TIRZEPATIDE vs TISLELIZUMAB TIRZEPATIDE vs TISOTUMAB VEDOTIN TIRZEPATIDE vs TISOTUMAB VEDOTIN-TFTV TIRZEPATIDE vs TITANIUM DIOXIDE\ZINC

Related Pages

TIRZEPATIDE Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased TIRZEPATIDE Demographics